Attached files

file filename
EX-5.1 - EX-5.1 - HYPERION THERAPEUTICS INCd498574dex51.htm
EX-23.1 - EX-23.1 - HYPERION THERAPEUTICS INCd498574dex231.htm

As filed with the Securities and Exchange Commission on March 7, 2013

Registration Statement File No. 333-            

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

HYPERION THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   2834   61-1512713

(State or other jurisdiction of

incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification Number)

601 Gateway Boulevard, Suite 200

South San Francisco, California 94080

(650) 745-7802

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

 

Donald J. Santel

Chief Executive Officer

Hyperion Therapeutics, Inc.

601 Gateway Boulevard, Suite 200

South San Francisco, California 94080

(650) 745-7802

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

 

Copies to:

 

Laura A. Berezin

Jon Layman

Hogan Lovells US LLP

525 University Avenue

Palo Alto, CA 94301

(650) 463-4000

 

Jeffrey S. Farrow

Chief Financial Officer

Hyperion Therapeutics, Inc.

601 Gateway Boulevard, Suite 200

South San Francisco, CA 94080

(650) 745-7802

 

Mark B. Weeks

David G. Peinsipp

Cooley LLP

3175 Hanover Street

Palo Alto, CA 94304

(650) 843-5000

 

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.  ¨

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  x 333-186880

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ¨

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer   ¨    Accelerated filer   ¨
Non-accelerated filer   x  (Do not check if a smaller reporting company)    Smaller reporting company   ¨

 

 

CALCULATION OF REGISTRATION FEE

 

 

Title of Each Class of

Securities to be Registered

 

Proposed

Maximum

Aggregate

Offering Price(1)

  Amount of
Registration Fee(1)

Common Stock, $0.0001 par value per share

  $11,104,688   $1,515

 

 

(1) The registration fee is calculated in accordance with Rule 457(o) under the Securities Act of 1933, as amended, based on the proposed maximum aggregate offering price. The registrant previously registered securities at an aggregate offering price not to exceed $57,500,000 on a Registration Statement on Form S-1 (File No. 333-186880), which was declared effective by the Securities and Exchange Commission on March 7, 2013. In accordance with Rule 462(b) under the Securities Act, an additional amount of securities having a proposed maximum aggregate offering price of $11,104,688 is hereby registered, which includes shares issuable upon the exercise of the underwriters’ over-allotment option.

 

 

This Registration Statement shall become effective upon filing with the U.S. Securities and Exchange Commission in accordance with Rule 462(b) under the Securities Act.

 

 

 


EXPLANATORY NOTE

This Registration Statement on Form S-1 (this “462(b) Registration Statement”) is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, for the purpose of registering an additional $11.1 million of shares of common stock, par value $0.0001 per share, of Hyperion Therapeutics, Inc. This 462(b) Registration Statement relates to the public offering of shares of common stock contemplated by the Registration Statement on Form S-1 (File No. 333-186880), which was initially filed on February 26, 2013, and which, as amended, was declared effective by the Securities and Exchange Commission on March 7, 2013. Pursuant to Rule 462(b), the contents of the Registration Statement on Form S-1 (File No. 333-186880), including the exhibits thereto, are hereby incorporated by reference into this 462(b) Registration Statement.


PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

 

Item 16. Exhibits and Financial Statement Schedules.

 

  (a) Exhibits

The exhibits to the registration statement are listed in the Exhibit Index attached hereto and incorporated by reference herein.

 

  (b) Financial Statements Schedules:

No financial statement schedules are provided, because the information called for is not required or is shown either in the financial statements or the notes thereto.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on this 7th day of March, 2013.

 

Hyperion Therapeutics, Inc.
By   

/s/ Donald J. Santel

  Donald J. Santel
  Chief Executive Officer and President

Pursuant to the requirements of the Securities Act of 1933, as amended, this Amendment to the Registration Statement has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

 

Signature

  

Title

 

Date

/s/    Donald J. Santel        

  

Chief Executive Officer, President and Director

(Principal Executive Officer)

  March 7, 2013
Donald J. Santel     

/s/    Jeffrey S. Farrow        

  

Chief Financial Officer

(Principal Financial and Accounting Officer)

  March 7, 2013
Jeffrey S. Farrow     

*

   Chairman of the Board   March 7, 2013
James I. Healy, M.D., Ph.D.     

*

   Director   March 7, 2013
Gaurav Aggarwal, M.D.     

*

   Director   March 7, 2013
David W. Gryska     

*

   Director   March 7, 2013
Bo Jesper Hansen, M.D., Ph.D.     

*

   Director   March 7, 2013
Robert Hopfner     

*

   Director   March 7, 2013
Jake R. Nunn     

*

   Director   March 7, 2013
Bijan Salehizadeh, M.D.     

*

   Director   March 7, 2013
Daniel G. Welch     

*

   Director   March 7, 2013
Lota S. Zoth     

 

* Pursuant to a Power of Attorney

 

By:  

/s/    Donald J. Santel        

  Donald J. Santel
  Attorney-in-Fact


EXHIBIT INDEX

 

Exhibit
No.

  

Description

  5.1    Opinion of Hogan Lovells US LLP.
23.1    Consent of PricewaterhouseCoopers LLP.
23.2    Consent of Hogan Lovells US LLP (included in Exhibit 5.1).
24.1    Previously filed on the signature page to the Registrant’s Registration Statement on Form S-1 (File No. 333-186880) filed by the Registrant with the Commission on February 26, 2013, and incorporated herein by reference.